

CURRICULUM VITAE

JOHN J. OPPENHEIMER, M.D.

PERSONAL INFORMATION:

Date of Birth: June 22, 1960

EMAIL: NALLOPP@pol.net

OFFICES:

Pulmonary and Allergy Assoc One Springfield Avenue Summit, NJ 07901 (908) 934-0440 (908) 934-0441 (FAX)	Pulmonary and Allergy Assoc 8 Saddle Road Suite 101 Cedar Knolls, NJ 07927
---	--

EDUCATION:

Lafayette College B.A. in Biology	1982
Temple University School of Medicine M.D.	1986

TRAINING:

Internship, Internal Medicine Robert Wood Johnson University Hospital (Formerly Rutgers University Hospital)	1986-87
Residency, Internal Medicine Robert Wood Johnson University Hospital (Formerly Rutgers University Hospital)	1987-89
Fellowship, Allergy and Clinical Immunology National Jewish Center for Immunology and Respiratory Medicine (Robert J. Suslow Fellow)	1989-91

ACADEMIC POSITIONS:

Staff Physician National Jewish Center for Immunology and Respiratory Medicine	1991-92
Instructor in Medicine University of Colorado Health Science Center	1991-92
Co-Director, Allergy and Asthma Research Center	

University of Medicine and Dentistry of New Jersey 1992-97
Clinical Associate Professor
University of Medicine and Dentistry of New Jersey 1999

WORK HISTORY:

Director Clinical Research
Pulmonary and Allergy Associates, PA 1995-present

COMMITTEES:

Skin Test Committee, American Academy of
Allergy and Immunology
Board of Directors, New Jersey Allergy Society 1993-Present
Board of Directors, American Lung Association
of New Jersey 1994-1999
President, New Jersey Allergy Society 1999-2000
Asthma Task Force Dept of Health of NJ 2003-
Practice Parameter Committee of the
AAAAI/ACAAI 2004
Vice Chair Clinical Therapeutics Committee AAAAI 2005-
Vice Chair Immunotherapy Committee ACAA 2005-
Member Indoor Air Quality Committee ACAA 2005-

LICENSE AND CERTIFICATIONS:

New Jersey State Medical License #MA050562
American Board of Internal Medicine 1989
American Board of Allergy and Immunology 1992

PROFESSIONAL SOCIETIES:

American Academy of Allergy and Immunology 1989-Present
American College of Allergy and Immunology 1989-Present
New Jersey Allergy and Immunology Society 1992-Present
New Jersey Allergy and Immunology Society
(Executive Board of Directors) 1994-Present
Morris County Medical Society 1997-Present

EDITORIAL BOARD:

Annals of Allergy, Asthma & Immunology 2004 -
Current Allergy Practice 1993-96
Chances Are (Editor in Chief) 1995-96
REVIEWER: Journal Allergy & Clinical Immunology 1998 -

HONORS AND AWARDS:

Cum Laude, Lafayette College
Hunt Prize for Research in Biology
(Thesis: Myelin as an Antigen)

Maroon Key Honor Society, Lafayette College
Von Pirquet Award, American College
of Allergy and Immunology
(For the "Best Abstract Submitted, 1991 Meeting)

ABSTRACTS:

Oppenheimer, J.J.; Bock, S.A.; Christensen, F.; Nelson, H.S.;
Leung, D.Y.M.; "Treatment of Peanut Allergy with Rush
Immunotherapy," Journal of Allergy and Clinical Immunology,
1992;89-297

Oppenheimer, J.J.; Nelson, H.S., "Seasonal Changes in Prick
Skin Test Reactivity," Annals of Allergy 1992;68:71

Oppenheimer, J.J.; Buchmeier, A.D.; Nelson, H.S., "Double-Blind
Trial of an Ultrasonic Heated Nasal Aerosol in the Treatment of
Perennial Allergic Rhinitis," Annals of Allergy, 1993;70:62

Oppenheimer, J.J.; Areson, J.; Nelson, H.S.; "Oral Cat
Immunotherapy," Journal of Allergy and Clinical Immunology,
1993;91:289

Giclas, P.; Oppenheimer, J.J.; Nelson, H.S.; Leung, D.Y.M.;
"Activated Charcoal as an Adsorbent for Ingested Food
Allergens," Journal of Allergy and Clinical Immunology;
1993:91:344

Wolff, A.H.; Oppenheimer, J.J.; Bielory, L.; "Comparison of
Metered Dose Inhaler Spacer Devices," Journal of Allergy and
Clinical Immunology, 1993;91:375

Huss, H.T.; Oppenheimer, J.J.; Bielory, L.; "Asthma Mortality
in the Garden State," Annals of Allergy 1994;P.44

Peltz, S.; Reyes, R.; Oppenheimer, J.J.; Druce, H.; Bielory,
L.; "Chronic Angioedema of the Tongue Heraldng the Onset of
Pernicious Anemia and Hashimoto's Thyroiditis." Annals of
Allergy 1994:192

Mitta, J.; Diaz, C.; Oppenheimer, J.J.; Bielory, L.; "Impact of
Increasing Aerobiological Changes from 1991-93," Annals of
Allergy 1995:P278.

Barchuk, W.; Fernandez, H.; Raveche, E.; Oppenheimer, J.J.;
Bielory, L.; "Peripheral Blood Cytokine Gene Expression in
Acute Exacerbations of Asthma Treated with Corticosteroids,"
Annals of Allergy 1995:P278.

Wolff A.H.; Oppenheimer J.J.; "Effect of Azelastine Nasal Spray
on Cutaneous Histamine Response," Annals of Allergy, Asthma
and Immunology 1998;80:84.

Milks, C.J.; Oppenheimer, J.J.; Bielory, L.; "ER Asthma Care Compared to National Guidelines," Annals of Allergy, Asthma and Immunology 1998;80:91.

Milks, C.J.; Oppenheimer, J.J.; Bielory, L.; "Use of National Asthma Education and Prevention (NAEPP) Guidelines to Improve Emergency Room Asthma Care" The Journal of Allergy and Clinical Immunology Feb 2001;107:S245.

Cain, W.T.; Oppenheimer, J.J. Evaluating the Proficiency of Community Pharmacists in Their Ability to Learn the Proper Actuation Technique of Three Inhaler Devices. J1 All Clin Immun 2001;107:S267.

Duffy, J.; Cain, W.T.; Oppenheimer, J.J. The Misconception of Using Floating Patterns as an Accurate Means of Measuring the Contents of Metered-dose Inhaler Devices. Ann All Asthma Immun

Chopra N, Oprescu N, Fask A, Oppenheimer J. Does introduction of new "easy to use" inhalational devices improve medical personnel's knowledge of their proper use? Chest 2001;120:143s.

Vannelli P, Youssef N, Rosh J, Oppenheimer J. Exploring the Link between eosinophilic esophagitis and esophageal foreign Bodies in the pediatric population. J1 All Clin Immun 2005;115:S241.

LETTERS TO THE EDITOR:

Cimetidine Prevents Erythema Multiforme (Response). Annals of Allergy. 1993;70:180.

Nelson, H.S.; Oppenheimer, J.J.; Vatsia, G.A.; Buchmeier, A.; "Sublingual Immunotherapy for Cat Allergy (reply), Journal of Allergy and Clinical Immunology. 1995;95:920-1.

Peltz, S.; Bateman, H.; Reyes, R.; Oppenheimer, J.; Bielory, L.; "Hypodermic Epinephrine Spray and Uvular Angioedema Revisited," Journal of Allergy and Clinical Immunology. 1996;97:717-8.

Oppenheimer J. Floating a metered-dose inhaler is not an accurate measure of remaining medicine. Ann Allergy Asthma and Immun. 2002;88:534.

PUBLICATIONS:

Oppenheimer, J.J.; Nelson, H.S.; "Case Report: An Unusual Reaction to Foods?," Annals of Allergy, 1992;68:17-21

Schmaling, K.; Rosenberg, S.; Oppenheimer, J.; Moran, M.; "Factitious Disorder with Respiratory Symptoms (case report)", Journal of Psychosomatics, 1991;32:457-97.

Oppenheimer, J.J.; Kirkpatrick, C.; "Urticaria," Update, 1991;1-4.

Oppenheimer, J.J.; Bock, S.A.; Christensen, F.; Nelson, H.S.; Leung, D.Y.M.; "Treatment of Peanut Allergy with Rush Immunotherapy," Journal of Allergy and Clinical Immunology, 1992;90:256-62.

Oppenheimer, J.J.; Nelson, H.S.; "Seasonal Changes in Prick Skin Test Reactivity," Annals of Allergy, 1993;71:227-9.

Oppenheimer, J.J.; Nelson, H.S.; "A Double-Blind, Placebo-Controlled Evaluation of Sublingual Immunotherapy with Standardized Cat Extract," Journal of Allergy and Clinical Immunology, 1993;92:229-36.

Hamilos, D.L.; Oppenheimer, J.J.; Yunginger, J.; Lockey, R.F.; Sullivan, T.; et al, "Suggested Approaches for Research Protocols Involving the Potential for Life-Threatening Reactions (Rostrum)," Journal of Allergy and Clinical Immunology, 1993;91:1101-20.

Oppenheimer, J.J.; Nelson, H.S.; "Double-blind Trial of a Heated Nasal Aerosol in the Treatment of Perennial Allergic Rhinitis," Journal of Allergy and Clinical Immunology, 1993;92:56-60.

Oppenheimer, J.J.; Areson, J.; Nelson, H.S.; "The Safety and Efficacy of Oralan Cat as an Oral Desensitization Compound for Cat Allergy," Journal of Allergy and Clinical Immunology, 1994;93:61-7.

Luca, R.; Oppenheimer, J.J.; Rasi, J.; Bielory, L.; "Reaction to Thiomersol," Journal of Allergy and Clinical Immunology, 1994;93:61-7.

Bielory, L.; Huss, H.; Oppenheimer, J.J.; "Asthma Morality in New Jersey," New Jersey Medicine, 1996;93:164-6.

Bielory, L.; Basile, F.; Palmisano, M.; Oppenheimer, J.J.; Orenstein, M.; "Chronic Pneumonia and Diarrhea," Annals of Allergy, Asthma and Immunology, 1997; 78:339-44.

Nelson, H.S.; Bucher, B.; Buchmeier, A.; Oppenheimer, J.; Garcia, J.; "Suppression of the Skin Reaction to Histamine by Ebastine," Annals of Allergy, Asthma and Immunology, 1995;74:442-447.

Oppenheimer, J.J.; Nelson, H.S.; "Oral and Sublingual Immunotherapy," Practical Allergy and Immunology, 1995;10:3-8.

Peltz, S.; Barchuck, W.; Oppenheimer, J.J.; Bielory, L.; "Chronic Angioedema of the Tongue Associated with Pernicious

Anemia and Hashimoto's Thyroiditis," Clinical and Experimental Dermatology, 1995;20:35-7.

Nelson, H.S.; Bucher, B.; Buchmeier, A.; Oppenheimer, J.J.; Garcia, J., "Suppression of Skin Reaction to Histamine by Ebastine," Annals of Allergy, 1995;74:442-7.

Nelson, H.S.; Oppenheimer, J.J.; Buchmeier, A.; Kordash, T.R.; Freshwater, L.L.; "An Assessment of the Role of Intradermal Skin Testing in the Diagnosis of Clinically Relevant Allergy to Timothy Grass," Journal of Allergy and Clinical Immunology," 1996;97:1193-201.

Oppenheimer, J.J.; "Inhalational Therapy in Asthma," Allergy and Asthma Proc., 1996;17:351-3.

Luka RE, Oppenheimer JJ, Miller N, Rossi J, Bielory L. Delayed hypersensitivity to thimerosal in Rh₀(D) immunoglobulin. J1 All Clin Immunol. 1997;100:138-9.

Derimanov GS, Oppenheimer J. Exacerbation of premenstrual asthma caused by and oral contraceptive. Ann Allergy Asthma Immunol. 1998;81:23-6.

Oppenheimer JJ, Bock SA. The ice cream parlor challenge could be a killer. J1 All Clin Immunol. 1998;102:325-6.

Cain WT, Cable G, Oppenheimer. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J1. All Clin Immunol. 2001;108:918-20.

Cain TW, Oppenheimer J. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001;87:417-9.

N, Oprescu N, Fask A, Oppenheimer J. Does introduction of new "easy to use" inhalational devices improve medical personnel's knowledge of their proper use? Chopra Ann Allergy Asthma Immunol. 2002;88:395-400.

Chan R, Oppenheimer J. Occupational allergy caused by Peruvian lily (Alstroemeria). Annals of Allergy Asthma and Immunol. 2002;88;638-9.

Oppenheimer JJ, Chipps B, Corbridge TC, Fanta CH. Acute asthma: The basics of assessment and treatment. J Respir Dis. 2002;23:126-43.

Oppenheimer JJ, Casale TB. Next generation antihistamines: therapeutic rationale accomplishments and advances. Expert Opin Investig Drugs. 2002;11:807-17.

Busse W., Koenig SM, Oppenheimer J., et.al. Steriod Sparing

effects of Fluticasone 100 mg and Salmeterol 50mg administered twice daily in a single product in patients previously controlled with Fluticasone 250 mg twice daily. *JL Allergy Clinical Immunology* 2003; 111:57-65.

Lieberman P, Kemp S, Oppenheimer et al. Anaphylaxis a revised practice parameter *Jl All Clin Immunol*. 2005; 116:S483-523.

Bonilla F., Bernstein I.L., Khan D., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *Annals of Allergy Asthma and Immunol* 2005;94:51-63.

Oppenheimer J. Anaphylaxis. Trying to bring meaning to uncertainty. *Annals of Asthma Allergy and Immunol*. 2005;95:211-2.

Li J, Oppenheimer J, Bernstein IL et al. Attaining asthma control. A practice parameter. *J Allergy Clin Immunol*. 2005;115:S3-11.

Slavin RG, Spector SL, Bernstein IL et al. The diagnosis and management of sinusitis: A practice parameter update. *J Allergy Clin Immunol* 2005;115:s13-47.

Oppenheimer J, Nelson HS. Skin Testing (A Review). *Ann Allergy Asthma and Clin Immunol* (in Press)

Oppenheimer J, Nelson HS. Skin Testing: A Survey of Allergists. *Ann Allergy Asthma and Clin Immunol* (in Press).

TEXTBOOK CHAPTERS:

Claman, H.; Oppenheimer, J.J.; "Angioedema," Book Chapter - In the *Internal Medicine Casebook: Real Patients, Real Answers,* New York, Little Brown and Co., 1994.

Bielory, L.; Oppenheimer, J.J.; "Asthma and Pregnancy," *Clinical Consultations in Obstetrics and Gynecology. Primary Care For the Gynecologist.* Edited by G. Weiss. 1995;49-56.

Oppenheimer, J.J.; Bielory, L.; "Reversible Obstructive Airway Disease", *Rehabilitation of the Patient with Respiratory Disease, Part IV, Chapter 24, McGraw-Hill Co.,* 1999.

Oppenheimer J. "Skin Testing" In *Immunology and Allergy Clinics of North America.* Edited by W. Dolen. W.B. Saunders. 2001.

PRIMARY RESEARCH INTERESTS:

Skin Tests: Seasonal changes in skin test reactivity, efficacy of intradermal skin testing.

Immunotherapy: Immunologic changes in Rush immunotherapy, efficacy of peanut immunotherapy, Efficacy of

oral immunotherapy.
Allergic Rhinitis: Efficacy of nasal washes.
Asthma: Crisis plan for outpatient assessment of asthma.
The magnitude of pollen granules measuring less than 5
microns.

CLINICAL INVESTIGATIONS:

Determination of the Safety and Efficacy of Novel Non-sedating Antihistamine in the Treatment of Seasonal Allergic Rhinitis: Double-Blind Comparison with Oxymetazoline and Placebo (Janssen Research Foundation), 1990

A Placebo-controlled, Double-Blind, Single-Dose Study of the Effect of a Novel Leukotriene Inhibitor on Pulmonary Function in Asthmatics (Rorer). 1990

The Safety and Efficacy of Oralan Cat as an Oral Desensitization Compound for Cat Allergy (Immunotech), 1991.

Double-Blind Trial of the Rhinotherm 2 in the Treatment of Perennial Allergic Rhinitis (Healthdyne Technologies), 1991.
A Novel Antihistamine/Placebo, Double-Blind, Randomized, Parallel Group Study of Patients with a History of Chronic, Stable, Reversible Asthma Requiring Bronchodilator Therapy (Bristol-Myers-Squibb), 1991.

A Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of a Single Dose of a Novel Non-sedating Antihistamine on Histamine Skin Response in Patients with Allergic Rhinitis (Rhone-Poulenc Rorer), 1991.

A Placebo-Controlled, Double-Blind, Multiple-Dose Study of a Novel PAF Antagonist in Moderate Asthmatics (Rhone-Poulenc Rorer), 1991.

A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Group-Comparative Study of the Safety and Effectiveness of Four-Dose Levels of a Novel Inhaled Steroid as Compared to Beclomethasone Dipropionate in the Treatment of Adults with Moderate Asthma (Fisons), 1991.

A Multi-center, Double-Blind, Multiple-Dose, Placebo-Controlled Dose Response Study of a Novel Antihistamine in Children with Seasonal Ragweed Allergy (Rhone-Poulenc Rorer), 1991.

A Trial of a Novel Long-Acting Beta Agonist Aerosol vs Placebo in Patients with Reversible Obstructive Airways Disease (Ciba-Geigy), 1991.

Dose Ranging: Six Weeks Therapy with Leukotriene Inhibitor on Bronchial Asthma (ICI Pharmaceuticals Group), 1992.

Analysis of the Sensitivity and Specificity of Puncture and Intradermal Skin Tests Using Standardized Timothy and Standardized Cat Extracts at Four Different Concentrations (Miles, Inc., Hollister-Stier Unit), 1992.

A Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of a Novel Alternative Propellant in Asthma MDI Therapy (3M), 1993.

Long Term Surveillance Study of a Novel Lipoxygenase Inhibitor Plus Usual Care vs Usual Care in Patients with Asthma. Asthma (Abbott Laboratories), 1994.

A Double-Blind, Placebo-Controlled, Double-Dummy Comparison of Clinical Efficacy and Safety of Vanceril MDI vs Azmacort MDI in Adult Asthmatics (Schering Corporation), 1994.

Bayer/Miles Multi-center III Trial Evaluation of a Novel Immediate Skin Test Device," 1995.

A Multi-center, Double-Blind, Placebo Controlled, Randomized Trial Evaluating the Safety and Efficacy of Aerobid M with and Without Aerochamber in Patients with Mild-Moderate Asthma (Forest 1996).

An Open Label, Noncomparative, Multi-center Trial to Evaluate Accolate in Patients with Asthma (Zeneca, 1996).

A Comparison of Salmeterol vs Theophylline vs Salmeterol Plus Theophylline in COPD Patients (Glaxo, 1997).

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Comparative Study of Fluticasone Propionate (88 mcg BID) vs Zafirulakast (20 mg BID), in Subjects Who Are Currently Receiving Beta-Agonists Alone (GLAXO 1997).

Aerobid Once-a-Day with AeroChamber in Mild to Moderate Asthma Patients (Forest 1997).

A 12-Week Comparison of HFA Aerobid vs CFC Aerobid in Patients with Mild to Moderate Asthma (Forest 1997).

A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (Raxar) 400mg or 600mg once daily and Clarithromycin (Biaxin) 500mg twice daily in the Treatment of Patients with Acute Bacterial Exacerbations of Chronic Bronchitis. (May 1998)

A Multicenter Evaluation of the Effects of Zyban (bupropion hydrochloride sustained release tablets) versus Placebo in Population of Smokers in COPD. (May 1998)

A Randomized Double-Blind, Parallel-Group, Comparative Trial of Inhaled Fluticasone Propionate 250mcg BID, 500mcg BID and Placebo BID via the Diskus in Subjects with Chronic Obstructive

Pulmonary Disease (COPD) (August 1998)

Randomized, parallel-group, Open-Label multicenter clinical study comparing the safety, efficacy, quality of life and socioeconomic variables of twice daily formoterol powder (12 ug bid) to twice daily salmeterol (50 ug bid) administered for six months to adult subjects with reversible obstructive airway disease (ROAD) (September 1998)

A study to Evaluate Subject Preference for Proventil HFA (Albuterol Sulfate Inhalation Aerosol) vs a Generic Albuterol Inhalation Aerosol: A Cross-Over Study (September 1998)

A Multiple Dose, Dose Ranging, Placebo and Active-controlled, comparison of Two Puffs of Budesonide solution delivered via the RESPIMAT (0, 25, 50, 100 and 200 mcg/inhalation) Device and two or four actuations of Pulmicort Turbuhaler (200 mcg/inhalation) administered twice a day in a one year, Double-Blind (within RESPIMAT Device), Safety, and Efficacy Study in Inhaled Corticosteroid Dependent Moderate to Severe Asthmatics. (April 1999)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Clinical Effect of 2 Oral Doses of Combination Montelukast/Loratadine with Placebo in Patients with Seasonal Allergic Rhinitis Who Also Have Asthma (March 1999)

A Randomized, Double-Blind, Parallel-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the Diskus Formulations of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination as Compared to P Placebo in COPD Patients (September 1999)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall Study (September 1999)

Efficacy and Safety of Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (September 1999)

A Multicenter, Randomized, Placebo-controlled, One-year Study of the Efficacy and Safety of ZYBAN vs Placebo as Aids to Smoking Cessation Treatment in Adult Cigarette Smokers previously treated with Bupropion (September 1999)

A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate combination Product 50/100 mcg BID via the Diskus inhaler vs Oral Montelukast 10 mg QD in Adolescents and Adults with Persistent Asthma (September 1999)

A Randomized, Double-Blind Multicenter Study to Evaluate the

effect of adding either Montelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics (October 1999)

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice Daily for Five Days in the Treatment of Influenza in Patients 12 Years or Over Diagnosed with Asthma or Chronic Obstructive Pulmonary Disease November (1999)

A Multicenter, Randomized, Double-Blind Pilot Study Comparing the Clinical Effect of Intravenous Montelukast with Placebo in Patients with Acute Asthma (February 2000)

A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100 mcg Diskus Inhaler BID vs Fluticasone Propionate 250 mcg Diskus inhaler BID in Adolescents and Adults with Moderate Persistent Asthma (February 2000)

A Multi-center, Double-Blind, Placebo-Controlled, Group Comparative Study to Investigate the Long-Term Safety of AR-C68397 AA via pMDI in Adult Patients with Chronic Obstructive Pulmonary Disease (February 2000)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis (March 2000)

Evaluation Of Uridine 5' - Triphosphate Solution for Inhalation (UTP) as an adjunct in the Diagnosis of Lung Cancer by Sputum Cytology (March 2000)

An Open-Label, Multicenter, Multinational, Uncontrolled Study of the Efficacy and Safety of Oral HMR 3647 (800 mg once daily) given for 7 days in the Treatment of Community-Acquired Pneumonia in Adults (March 2000)

A Double-Blind, Randomized, Placebo and Active Controlled, Multicenter, Parallel Group, Dose-Ranging, Study of L-753099 in Patients with COPD (Mar 2000)

A Randomized, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Three Once Daily Doses of BAY 19-8004 with Placebo and Montelukast 10 mg Daily in Patients with Symptomatic Asthma (April 2000)

A Multicenter, Multinational, Double-blind, Double-dummy, Placebo-controlled, Group Comparative Study to Investigate the

Effects of AR-C68397AA via pMDI compared with Salmeterol in Adult Patients with Chronic Obstructive Pulmonary Disease (June 2000)

A Double-Blind, Double Dummy, Randomized, Parallel Group Comparison of 200 mcg Fluticasone Propionate Aqueous Nasal Spray, Placebo and 10 mg Encapsulated Loratadine Administered as needed in Subjects with SAR (August 2000)

Efficacy and Safety of Combination Loratadine/Montelukast QD vs its Components vs Placebo in the Treatment of Subjects with SAR (Aug 2000)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients with SAR (Aug 2000)

"A Randomized, Double-Blind, Multicenter Study to Evaluate the Effect of Oral Montelukast Sodium versus Inhaled Fluticasone Propionate in Patients With Mild Persistent Asthma", Protocol 163-00/SNG480 (November 2000)

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered once a day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community -Dwelling High Risk Subjects aged >12 yrs (Jan 2001)

An Observational Study of the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) (Jan 2001)

A Double-Blinded, Placebo-Controlled, Parallel Group Study of Uridine 5'-Triphosphate(UTP)solution for inhalation as an adjunct in the diagnosis of lung cancer by sputum cytology. INSPIRE 01-312 (January 2001)

A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the safety of Olizumab in Moderate to Severe Persistent Asthma Subjects Already Treated with Other Therapies (Feb 2001)

A Randomized, Double-Blind, Double-Dummy, Comparative Trial of Eight Week Courses of Salmeterol Xinafoate Versus Salmeterol Xinafoate Plus Ipratropium Bromide vs Placebo in Subjects with COPD (Feb 2001)

An Open-Label, Multicenter, Single Group Study to Assess the Bacteriological Eradication, Clinical Efficacy and Safety of Oral Gemifloxacin 320 mg Given Once Daily for Five Days in the Treatment of ABS (Feb 2001)

An Open-Label, Multicenter, Multinational, Uncontrolled Study of the Efficacy and Safety of 7 days of Oral Telithromycin (800

mg once daily) in the treatment of CAP due to Streptococcus pneumoniae in Adolescents and Adults (Feb 2001)

The Efficacy and Safety of 5 Days of Oral Telithromycin (800 mg Once Daily) in the Treatment of Acute Exacerbation of CB (Feb 2001)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Study Comparing the Effects of Three Doses of INS365 to Placebo Administered via the Pari LC Star Nebulizer on Symptoms and Respiratory Health Status in Patients with Mild to Moderate Chronic Bronchitis (Mar 2001)

"A Multi-Center, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of a Four-week Course of Fluticasone Propionate Aqueous Nasal Spray (200 mcg QD) on Ocular Symptoms Commonly Associated with Allergic Rhinitis" (March 2001)

GW SC030003 A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to investigate the long-term effects of Salmeterol/Fluticasone Propionate

Seretide™/Viani™/Advair™) 50/500µg BD, Salmeterol 50µg BD, and Fluticasone Propionate 500µg BD, all delivered via the diskus™ inhaler on the survival of subjects with chronic obstructive pulmonary disease (copd) over 3 years of treatment. (April 2001)

A Double Blind, Placebo-Controlled Study of Tecastemizole in Subjects With Seasonal Allergic Rhinitis and Concomitant Asthma. (June 2001)

SB 207499/168, "A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Ariflo 15 mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease. (COPD) (August 2001)

A Double-blind, Double-dummy, Parallel-group, Multi-center, Randomized Study of Fexofenadine HCl 180 mg vs Ceterizine HCl 10 mg in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall Allergy Season. (August 2001)

A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison Of Salmeterol Xinafoate Inhalation Aerosol Versus Ipratropium Bromide and Albuterol Sulfate Inhalation Aerosol In Subjects With Chronic Obstructive Pulmonary Disease. (September 2001)

A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, 4-Period, Crossover Study to Investigate the Bronchodilating Effect of L-454560 and L-454560 /Montelukast Combination in Adult Patients With Stable, Mild-to-Moderate Asthma (November 2001)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (November 2001)

A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 µg/day and 200µg/day (ex-valve) Administered Once Daily on Growth in Children with Mild Persistent Asthma. (November 2001)

BYK217/FK1 "12 Weeks treatment with 125µg roflumilast versus 250µg roflumilast versus placebo in patients with asthma"(December 2001)

GSK40037 "A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID, Fluticasone Propionate DISKUS 100mcg BID, Salmeterol Xinafoate DISKUS 50 mcg BID, or Oral Montelukast 10mg QD" (January 2002)

Pfizer 1067 "A Randomized, Multicenter, Third Party Blinded Study Comparing the Efficacy, and Safety of Zithromax (Azithromycin) for 3 days (1.5 grams) Versus Avelox (Moxifloxacin Hydrochloride) for 5 days (2.0 grams) in the Outpatient Treatment of Acute Exacerbations of Chronic Bronchitis (AECB)" (January 2002)

Sepracor 914 "A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease" (February 2002)

Otsuka 210 "A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Dose Comparison Study of the Efficacy and Safety of Oral 25 mg, 75 mg OPC 6535, and Placebo in the Treatment of Patients Chronic Obstructive Pulmonary Disease" (May 2002)

Novartis CFOR258D US06 "A Randomized, Multicenter, Open-label, Parallel Group study comparing the efficacy and safety of Foradil Aerolizer 12ug BID to Servent MDI 50ug BID in patients with COPD" (May 2002)

Sepracor 051-353 "An Efficacy, and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older with Asthma." (June 2002)

AZ SD-039-0716 "A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of SYMBICORT (80/4.5

mcg) versus its Mono-Products (budesonide and formoterol in Children (>=6 Years of Age) and Adults with Asthma" (August 2002)

BI 1012.46 " A Comparison of Ipratropium Bromide/Salbufamol delivered by the Respimat inhaler to Ipratropium Bromide Respimat, COMBIVENT Inhalation Aerosol and Placebo of each formulation in a 12-week, double-blind, safety and efficacy study in adults with Chronic Obstructive Pulmonary Disease" (September 2002)

BI 205.235 "A Randomized, Double-blind, Placebo-controlled, Parallel group trial assessing the rate of decline of lung function with Tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD)" (October 2002)

Merck 289 A Multicenter, DOUBLE BLINE, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate The clinical effect of Montelukast Versus Placebo during the allergy season in patients with seasonal Aeroallergen Sensitivity and chronic asthma which is also active during allergy season. (January 2003)

ITGI P03180 "Preference Evaluation of Clarinex Tablets vs Zyrtec Tablets in Subjects with Symptomatic Allergic Rhinitis" (March 2003)

Novartis CFOR258D 2307 "A Randomized, Multicenter, Placebo-controlled parallel group study of four months duration per patient to evaluate the safety and efficacy of treatment with 24 ug BID and 12 ug Bid formoterol, double-blind, and 12 ug BID formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patient with persistent stable asthma" (May 2003)

Merck 269 "A Multicenter, Double-blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients with Seasonal Allergic Rhinitis and Chronic Asthma-Spring 2003" (May 2003)

AZ Symbicort D5896C00001 A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Dummy, Multicenter, 12 week study to assess the efficacy and safety of Symbicort®mdl 160/4.5 µg X 2 Actuations once-daily (qd) compared to Symbicort pMDl 80/4.5 µg x 2 Actuations qd, Symbicort pmdl 80/4.5 µg 2 Actuations twice-daily (bid) and to Budesonide pmdl 160 µg x 2 Actuations qd in asthmatic subjects 12 years of age and older (August 2003)

ITGI P03284-18 Efficacy and Safety of Desloratadine 10 mg daily versus placebo in subjects with allergic airway disease during the pollen season. (August 2003)

Merck 265 A Multicenter, Double-Blind, Randomized, placebo-Controlled, Parallel-Group Study investigating the clinical effects of Montelukast in patients with Perennial Allergic Rhinitis (September 2003)

PROPER AECB Patient Reported Outcomes, Productivity and Resource Utilization in outpatient treatment of Acute

Exacerbations of chronic bronchitis (AECB) Zithromax Tri Pak (AZITHROMYCIN) Versus Usual Care: A Prospective, Multicenter Observational Study. (October 2003)

SmithKline Beecham Corporation doing business as GlaxoSmithKline - Protocol No: SC030003 Phase III Study: A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (Seretide TM/VianiTM/AdvairTM) 50/500ug bd, salmeterol 50ug bd and fluticasone propionate 500ug bd, all delivered via the DiskusTM/AccuhalerTM inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. (April 2001)

Altana BY217/M2-111 Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. A 52 week, multicenter, double-blind study with 500 mcg roflumilast once daily versus placebo. (January 2004)

Dey, L.P. DL-059 - A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease, Followed by a 40-Week Open-Label Safety Extension (February 2004)

Altana BY9010/M1-404 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term (48 weeks) Safety of Ciclesonide, Applied as a Nasal Spray (200ug, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older. (March 2004)

DL-401 A 12-week randomized, single-blind, 3-arm parallel study to evaluate efficacy, QOL, and patient satisfaction between DuoNeb® via nebulizer, Combivent® MDI and concomitant DuoNeb® with Combivent® MDI in COPD patients. (March 2004)

Novartis Protocol Number: CQAB149B2205 - Novartis Pharmaceuticals trial entitled: "A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered

via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD).

Post-Text Supplement: 1 - Biomarker sub-study for CQAB149B2205 entitled: "A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD). (July 2004)

GSK SCO40043 A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the annual Rate of Moderate/Severe Exacerbations in subjects with Chronic Obstructive Pulmonary Disease (COPD). (August 2004)

GSK FFR30002: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg for 4 Weeks in Adult and Adolescent Subjects (≥12 years of age) with Perennial Allergic Rhinitis (PAR) (November 2004)

AstraZeneca Study D5899C00002: A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of SYMBICORT® pMDI 2 x 160/4.5 mcg and 80/4.5 mcg bid Compared to Formoterol TBH, Budesonide pMDI (and the combination) and Placebo in COPD Patients. (December 2004)

Takeda 01-04-TL-375-041 A Randomized, Double-blind, Placebo-Controlled study to assess the subjective response to treatment with Ramelteon (TAK-375) in adult subjects with chronic insomnia by utilizing an interactive voice response system (IVRS) for collecting diary data. (January 2005)

Aventis-Ketek Protocol HMR3647A/4019: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycin versus Azithromycin in Outpatients with Community-Acquired Lower Respiratory Tract Infections. (February 2005)

Sanofi -Synthelabo CPR-LTES5407-EN-E01 -Evaluation of the long-term efficacy and safety of zolpidem-MR 12.5-mg compared to placebo, when both are administered over a long-term period "as needed", in patients with chronic primary insomnia. (A randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIIb clinical study). (February 2005)

Dey, L.P. Protocol 201-065 - A 12-week Double-Blind, Parallel-Group, Placebo- and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg in the Treatment of Patients with Chronic Obstructive Pulmonary Disease (April 2005)

Intermune Protocol GIPF-007 - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. (August 2005)

8/2005